Home » Authors » Tiffany Turner

Articles by Tiffany Turner

Middlebrook Gets $100M and a New Management Team

Nov. 1, 2011

By Tiffany Turner

No Abstract

IDM Pleased with Data from Osteosarcoma Program

Nov. 1, 2011

By Tiffany Turner

No Abstract

LigoCyte Sets Series C Terms: $28M for Vaccine Development

Nov. 1, 2011

By Tiffany Turner

No Abstract

NewCo News: Cortria Aims to Capitalize on Dyslipidemia Market

July 21, 2008

By Tiffany Turner

BioAlliance Stops Doxorubicin Trial After Pulmonary Reactions

July 17, 2008

By Tiffany Turner

Avastin, Tarceva Sales Boost Genentech's Quarterly Earnings

July 16, 2008

By Tiffany Turner

Neurogen Halts Dosing of Adipiplon in Insomnia

July 15, 2008

By Tiffany Turner

Big Pharmas Team Up to Link Technology and Business Needs

July 11, 2008

By Tiffany Turner

SGX Shares Soar on Merger Giving Lilly Technology Boost

July 10, 2008

By Tiffany Turner

Seattle Genetics Nets $4M in Deal with Daiichi Sankyo

July 9, 2008

By Tiffany Turner

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...